FDA adds rare eye condition warning to popular GLP-1 medications
On Nov. 9, the U.S. Food and Drug Administration (FDA) announced it will require manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
Read original article on The Medical News →